These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3313678)

  • 1. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa.
    Rasmussen SN; Lauritsen K; Tage-Jensen U; Nielsen OH; Bytzer P; Jacobsen O; Ladefoged K; Vilien M; Binder V; Rask-Madsen J
    Scand J Gastroenterol; 1987 Sep; 22(7):877-83. PubMed ID: 3313678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
    Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
    Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a slow-release 5'-aminosalicylic acid preparation on disease activity in Crohn's disease.
    Saverymuttu SH; Gupta S; Keshavarzian A; Donovan B; Hodgson HJ
    Digestion; 1986; 33(2):89-91. PubMed ID: 3512352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease.
    Griffiths A; Koletzko S; Sylvester F; Marcon M; Sherman P
    J Pediatr Gastroenterol Nutr; 1993 Aug; 17(2):186-92. PubMed ID: 8229546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
    Singleton JW; Hanauer SB; Gitnick GL; Peppercorn MA; Robinson MG; Wruble LD; Krawitt EL
    Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease.
    Mahida YR; Jewell DP
    Digestion; 1990; 45(2):88-92. PubMed ID: 2190851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
    Schreiber S; Howaldt S; Raedler A
    Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Florent C; Cortot A; Quandale P; Sahmound T; Modigliani R; Sarfaty E; Valleur P; Dupas JL; Daurat M; Faucheron JL; Lerebours E; Michot F; Belaiche J; Jacquet N; Soulé JC; Rothman N; Gendre JP; Malafosse M
    Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):229-33. PubMed ID: 8724022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
    Gastroenterology; 1993 Feb; 104(2):435-9. PubMed ID: 8425685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.
    Hanauer SB; Strömberg U
    Clin Gastroenterol Hepatol; 2004 May; 2(5):379-88. PubMed ID: 15118975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].
    Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
    Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update.
    Martin F
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):57S-63S. PubMed ID: 2891469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
    Sutherland LR; Martin F; Bailey RJ; Fedorak RN; Poleski M; Dallaire C; Rossman R; Saibil F; Lariviere L
    Gastroenterology; 1997 Apr; 112(4):1069-77. PubMed ID: 9097988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.
    Tremaine WJ; Schroeder KW; Harrison JM; Zinsmeister AR
    J Clin Gastroenterol; 1994 Dec; 19(4):278-82. PubMed ID: 7876505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.
    Gross V; Andus T; Fischbach W; Weber A; Gierend M; Hartmann F; Schölmerich J
    Z Gastroenterol; 1995 Oct; 33(10):581-4. PubMed ID: 7502549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease.
    Prantera C; Pallone F; Brunetti G; Cottone M; Miglioli M;
    Gastroenterology; 1992 Aug; 103(2):363-8. PubMed ID: 1634054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE; Schraa CC
    Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Crohn's disease with peroral 5-aminosalicylic acid.
    Rasmussen SN; Binder V; Maier K; Bondesen S; Fischer C; Klotz U; Hansen SH; Hvidberg EF
    Gastroenterology; 1983 Dec; 85(6):1350-3. PubMed ID: 6354827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.